5-氨基甲基-2-氰基吡啶 | 181130-14-3

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 5-氨基甲基-2-氰基吡啶
• 中文别名: 5-(氨基甲基)-2-吡啶甲腈(9ci)
• 英文名称: 5-(aminomethyl)pyridine-2-carbonitrile
• 英文别名: 5-(aminomethyl)picolinonitrile；5-aminomethyl-2-cyanopyridine；5-aminomethyl-pyridine-2-carbonitrile；2-cyano-5-(aminomethyl)pyridine
• CAS: 181130-14-3
• 化学式: C₇H₇N₃
• mdl: MFCD08457627
• 分子量: 133.153
• InChiKey: ZIFSWCUCJMIKQC-UHFFFAOYSA-N

物化性质

• 沸点：
  325.2±32.0 °C(Predicted)
• 密度：
  1.17

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  5-氨基甲基-2-氰基吡啶 在 N-甲基吗啉 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1

  摘要：

  A series of noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at PI was investigated. While the amidrazone and the amine series displayed limited oral absorption, the amidine series demonstrated generally good oral absorption and strong antithrombotic activity; the single-digit picomolar K-i achieved from this series is among the best yet reported. The present work highlights the benzamidine compound 11f (LB30812) that exhibits excellent overall profiles of potency, oral absorption and antithrombotic efficacy. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00093-8
• 作为产物：
  描述：

  2-氰基-5-甲基吡啶 在 N-溴代丁二酰亚胺(NBS) 、 sodium hydride 、 三氟乙酸 、 过氧化苯甲酰 作用下， 以 四氢呋喃 、 四氯化碳 、 二氯甲烷 为溶剂， 生成 5-氨基甲基-2-氰基吡啶
  参考文献：
  名称：

  Noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1

  摘要：

  A series of noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at PI was investigated. While the amidrazone and the amine series displayed limited oral absorption, the amidine series demonstrated generally good oral absorption and strong antithrombotic activity; the single-digit picomolar K-i achieved from this series is among the best yet reported. The present work highlights the benzamidine compound 11f (LB30812) that exhibits excellent overall profiles of potency, oral absorption and antithrombotic efficacy. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00093-8

文献信息

• Mandelic acid derivatives and their use as throbin inhibitors
  申请人：——

  公开号：US20040019033A1

  公开（公告）日：2004-01-29

  There is provided a compound of formula I 1 wherein R a , R 1 , R 2 , Y and R 3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供了一种公式I的化合物 1 其中R a , R 1 , R 2 , Y和R 3 具有说明书中给出的含义以及药学上可接受的衍生物（包括前药），这些化合物和衍生物可用作竞争性胰蛋白酶样蛋白酶抑制剂，如凝血酶，因此，特别是用于需要抑制凝血酶的情况（例如血栓形成）或作为抗凝剂。
• [EN] ISOINDOLINE DERIVATIVES COMPRISING AN ADDITIONAL HETEROCYCLIC GROUP AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS<br/>[FR] DÉRIVÉS ISOINDOLINE COMPRENANT UN GROUPE HÉTÉROCYCLIQUE SUPPLÉMENTAIRE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES DE LA DOULEUR
  申请人：ASTRAZENECA AB

  公开号：WO2009145718A1

  公开（公告）日：2009-12-03

  Compounds of formula I are claimed, wherein R1is hydrogen, C1_3alkyl, C1_3alkoxy, cyano, hydroxy or halo; wherein C1-3alkyl may optionally be substituted by one or more substituents independently selected from hydroxy, C1-3alkoxy orfluoro; and wherein Ci^alkoxy may optionally be substituted by one or more fluoro; m is 1 or 2; R2 and R3 is each and independently selected from hydrogen, Ci_4haloalkyl, C1_4haloalkoxy, halo, C1_4alkoxy, C1_4alkyl and C3_7cycloalkyloxy; and wherein said C3_7cycloalkyloxy may optionally be substituted by one or more fluoro; and whereas both R2 and R3 can not be hydrogen; Het is selected from any one of pyridinyl, pyrazinyl, isoxazolyl, pyrazolyl, indolyl, triazolyl and pyrimidinyl, wherein each such heteroaryl may optionally be substituted by one or more X4; X4 is halo, C1-3alkyl, C1-3alkyl0C1-3alkyl, -CH(CH3)-O-C(CH3)3,C1_4alkoxy, cyano, or hydroxyl, or Ci_2hydroxyalkyl;; and wherein said C1-3alkyl, C 1-3alkylOC1-3alkyl, -CH(CH3)-O-C(CH3)3, or C1_4alkoxy may each optionally be substituted by one or more fluoro; L1 is C1_4alkylene, which may optionally be fluorinated or hydroxylated; and L2 is C1-3alkylene; with the exception of the compounds: 2-[1-(1,5-dimethyl-lH-pyrazol-4-yl)ethyl]-5,7-dimethoxy-3-oxo-N-[2-(trifluoromethyl)benzyl]isoindoline-1-carboxamide; N-(4-fluorobenzyl)-3-oxo-2-(-pyridin-4-yletyl)isoindoline-1-carboxamide and N-(2-chlorobenzyl)-2[2-(1H-indol-3-yl)-1-methyletyl]-3-oxoisoindoline-1-carboxamide; The invention further relates to pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

  公式I的化合物被要求，其中R1是氢，C1-3烷基，C1-3烷氧基，氰基，羟基或卤素；其中C1-3烷基可以选择性地被一个或多个取代基取代，这些取代基独立地选自羟基，C1-3烷氧基或氟基；而C1-3烷氧基可以选择性地被一个或多个氟基取代；m为1或2；R2和R3分别且独立地选自氢，C1-4卤代烷基，C1-4卤代烷氧基，卤素，C1-4烷氧基，C1-4烷基和C3-7环烷氧基；其中所述的C3-7环烷氧基可以选择性地被一个或多个氟基取代；而且R2和R3都不能是氢；Het选自吡啶基，吡嗪基，异噁唑基，吡唑基，吲哚基，三唑基和嘧啶基中的任何一种，其中每种这样的杂环烷基可以选择性地被一个或多个X4取代；X4是卤素，C1-3烷基，C1-3烷氧基C1-3烷基，-CH(CH3)-O-C( )3，C1-4烷氧基，氰基，或羟基，或C1-2羟基烷基；而所述的C1-3烷基，C1-3烷氧基C1-3烷基，-CH( )-O-C( )3，或C1-4烷氧基可以选择性地被一个或多个氟基取代；L1是C1-4烷基，可以选择性地被氟化或羟基化；而L2是C1-3烷基；除了以下化合物：2-[1-(1,5-二甲基-1H-吡唑-4-基)乙基]-5,7-二甲氧基-3-氧代-N-[2-(三氟甲基)苯甲基]异吲哚啉-1-羧酰胺；N-(4-氟苯甲基)-3-氧代-2-(-吡啶-4-基乙基)异吲哚啉-1-羧酰胺和N-(2-氯苯甲基)-2[2-(1H-吲哚-3-基)-1-甲基乙基]-3-氧代异吲哚啉-1-羧酰胺；本发明还涉及含有所述化合物的药物组合物以及所述化合物在治疗中的使用。
• [EN] PHARMACEUTICAL COMBINATION<br/>[FR] COMBINAISON PHARMACEUTIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2003101956A1

  公开（公告）日：2003-12-11

  There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.

  提供了一种组合产品，包括：(1) WO 02/44145中权利要求1的化合物或WO 02/44145中权利要求20的化合物（或其衍生物）或药用可接受的衍生物；以及（1）WO 01/28992中权利要求1定义的化合物或（2）WO 01/28992中权利要求34的化合物或（3）化合物A或B或C或D（或药用可接受的盐）用于治疗心律不齐或其凝血控制的并发症。
• [EN] N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES USEFUL AS HIF PROLYL HYDROXYLASE INHIBITORS<br/>[FR] DÉRIVÉS DE N-(BENZYLE OU PYRIDINYLMÉTHYL À SUBSTITUTION CYANO)-3-HYDROXYPICOLINAMIDE UTILES EN TANT QU'INHIBITEURS DE HIF PROLYL HYDROXYLASE
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2019060850A1

  公开（公告）日：2019-03-28

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R3, R4 R5, R6, R7, R8, R9, X1 and X2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with PHD.

  揭示了式1的化合物及其药用可接受的盐，其中R3、R4、R5、R6、R7、R8、R9、X1和X2在规范中有定义。本公开还涉及制备式1化合物的材料和方法，包括含有它们的药物组合物，以及它们用于治疗与PHD相关的疾病、疾患和状况的用途。
• Pyrimidine derivatives as ghrelin receptor modulators
  申请人：Kosogof Christi

  公开号：US20050070712A1

  公开（公告）日：2005-03-31

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

  本发明涉及式(I)的化合物，或者其治疗上适宜的盐或前药，该化合物的制备、含有该化合物的组合物以及在预防或治疗由生长激素释放素调节的疾病中使用该化合物，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。